[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteosarcopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteosarcopenia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100584444","rheumatoid-arthritis-and-osteosarcopenia-associated-factors-100584444",false,"NCT06889415","Rheumatoid Arthritis and Osteosarcopenia: Associated Factors","The Frequency of Osteosarcopenia in Patients With Rheumatoid Arthritis and the Factors Affecting the Sarcopenia-osteoporosis Relationship","Inclusion criteria:\n\n1. Being diagnosed with RA according to the ACR\u002FEULAR 2010 criteria\n2. Being a female or male over the age of 50\n3. Having the mental and physical capacity to complete the study questionnaires and tests\n4. Providing voluntary consent to participate in the study by signing the Informed Consent Form\n\nExclusion Criteria:\n\n1. Having an acute illness\u002Fdisability or significant cognitive impairment that prevents understanding and performing the required tests\n2. Having thyroid or parathyroid disease, uncontrolled diabetes, Cushing's syndrome, anemia.\n3. History of malignancy\n4. Severe cardiovascular disease, enal failure, advanced-stage COPD, decompensated liver disease\n5. History of gastrointestinal (GIS) surgery\n\n7-Having another coexisting autoimmune\u002Finflammatory rheumatic disease (e.g., SLE, Ankylosing Spondylitis, etc.), psoriatic arthritis, vasculitis, familial Mediterranean fever...)\n\n8-Having severe\u002Fsymptomatic hand osteoarthritis and\u002For deformities\n\n9-Severe\u002Fsymptomatic osteoarthritis in the knee, lumbar, hip, or ankle region\n\n10-Having Carpal Tunnel Syndrome, De Quervain, lateral epicondylitis, cubital tunnel syndrome or a history of traumatic hand injury\n\n11-Having a significant neurological disease, stroke, MS, myopathy, Parkinson's disease, radiculopathy\u002Fpolyneuropathy\u002Fbrachial plexopathy or others nerve root compressions\n\n12-History of surgical intervention on the upper and lower extremities or spine\n\n13-Having severe kyphosis or scoliosis\n\n14-Having any others disease causing balance disorders (neurological, orthopedic, metabolic, etc.)\n\n15-Having a major\u002Fsignificant psychiatric disorder (based on the medical history, and hospital records)\n\n16-Current use of androgens or estrogens\n\n17-Having prostheses, being fully dependent, or immobilized",true,"ALL","50 Years",{"count":20,"type":21},200,"ESTIMATED","1 Day","OBSERVATIONAL","Our study is a cross-sectional study, and its aim is to compare and analyze the prevalence of sarcopenia and osteoporosis in patients with rheumatoid arthritis (RA) with a control group and to reveal the impact of sarcopenia on osteoporosis, fall risk, and fracture risk. This prospective cross-sectional study will include 100 rheumatoid arthritis patients and 100 healthy controls, matched for age and sex. Patients will be consecutively and meticulously enrolled based on inclusion and exclusion criteria.\n\nA detailed medical history and examination will be performed on the patients, and their clinical and sociodemographic characteristics will be recorded. Blood tests for RA (RF, Anti-Cyclic Citrullinated Peptide (anti-CCP), CRP, ESR) and disease activity levels (DAS28) will be recorded. The prevalence of osteosarcopenia will be assessed in both the RA and healthy control groups.These groups will be evaluated using various scales and tests (including power, performance tests) including musculoskeletal ultrasonographic measurements and clinical functional assessment tests. he sarcopenic group will be categorized based on the level of sarcopenia, according to the new ISarcoPRM criteria (non-sarcopenic, dynapenic, sarcopenic, and severe sarcopenic). Osteosarcopenia will be evaluated for both groups, and the collected data will be analyzed with primary and secondary outcomes. The analysis will explore the potential relationships between rheumatoid inflammation, sarcopenia, and osteoporosis.",[26,27,28],"Osteosarcopenia","Rheumatoid Arthritis (RA)","Sarcopenia",[30,31,32,33],"osteosarcopenia","sarcopenia","Ultrasonography","rheumatoid arthritis","RECRUITING","2025-07-05",{"date":37,"type":38},"2025-07-10","ACTUAL",{"date":40,"type":38},"2023-08-15",{"date":42,"type":21},"2025-11-30",{"name":44,"class":45},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100560454","osteosarcopenia-in-axial-spondyloarthritis-100560454","NCT06577350","Osteosarcopenia in Axial Spondyloarthritis","The Frequency of Osteosarcopenia and Its Relationship With Demographic and Clinical Factors in Axial Spondyloarthritis","Inclusion Criteria:\n\nPatient group:\n\n* Participants with a diagnosis of AxSpA: Participants with diagnosis of Ankylosing Spondylitis according to the modified New York criteria and participants with diagnosis of non-radiographic Spondyloarthritis (SpA) according to the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria.\n* Aged 18-65 years\n* Who gave consent to participate in the study\n\nHealthy control group:\n\n* Age- and gender-matched healthy participants (age 18-65)\n* Who gave consent to participate in the study\n\nExclusion Criteria:\n\n1. Systemic high-dose steroid use (\\>5mg\u002Fday of prednisone for more than 3 months)\n2. Possible other causes of secondary sarcopenia (uncontrolled diabetes, chronic heart failure, thyroid\u002Fparathyroid disease, chronic renal failure, chronic liver failure)\n3. Hand-related disorders\u002Fdiseases that could affect the healthy assessment of grip strength\n4. Use of any medication that could potentially affect the bone metabolism (bisphosphonates, teriparatide, anticonvulsants, heparin, and anticoagulants)\n5. Psoriasis, inflammatory bowel disease\n6. Infection in the thigh area where ultrasonographic evaluation will be performed\n7. Body weight over 100 kg (contraindication to be positioned in the BMD device)\n8. Presence of malnutrition (individuals scoring 11 or below on the Mini Nutritional Assessment-Short Form (MNA))","18 Years","65 Years",{"count":57,"type":21},97,"Axial spondyloarthritis is a chronic inflammatory disease affecting the spine, sacroiliac joints, entheses, and sometimes peripheral joints with a close link to HLAB27. Typical features include inflammatory back pain, limited spinal mobility, and sacroiliitis. The term axial spondyloarthritis (AxSpA) includes both Ankylosing Spondylitis (AS) where sacroiliitis is diagnosed by X-rays, and non-radiographic AxSpA, where sacroiliitis is diagnosed via magnetic resonance imaging (MRI).\n\nOsteoporosis is common in AS patients, and sarcopenia may also develop due to inflammation and immobilization. Osteosarcopenia, the co-occurrence of osteoporosis and sarcopenia, might have an impact on morbidity and mortality of AxSpA patients.\n\nThis cross-sectional study aims to determine the frequency of osteosarcopenia in AxSpA patients and to investigate its relationship with various demographic and clinical factors. A control group with similar age and gender distribution will be recruited to evaluate osteosarcopenia. Our hypothesis is that osteosarcopenia will be more frequent in the AxSpA group compared to the control group. The study will also identify the demographic and clinical factors associated with osteosarcopenia in AxSpa.",[60,61,62,63,28,26],"Axial Spondyloarthritis","Ankylosing Spondylitis","Axial Spondyloarthritis, Non-Radiographic","Osteoporosis",[60,61,65,63,28,26],"Non-Radiographic Axial Spondyloarthritis","2024-08-28",{"date":68,"type":38},"2024-08-29",{"date":70,"type":38},"2023-09-01",{"date":72,"type":21},"2025-04",{"name":74,"class":75},"Ankara University","OTHER"]